CGP039937A | 144205-77-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: CGP039937A
• 英文别名: 6-(6-Carbamimidoylpyridin-2-yl)pyridine-2-carboximidamide
• CAS: 144205-77-6
• 化学式: C₁₂H₁₂N₆
• 分子量: 240.267
• InChiKey: UUSJIECFMYLBBU-UHFFFAOYSA-N

物化性质

• 沸点：
  489.6±55.0 °C(Predicted)
• 密度：
  1.45±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  126
• 氢给体数：
  4
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  [2,2']Bipyridinyl-6,6'-dicarboximidic acid dimethyl ester 在 氨 、 氯化铵 作用下， 以 甲醇 、 乙醇 为溶剂， 反应 1.0h， 生成 CGP039937A
  参考文献：
  名称：

  S-Adenosylmethionine decarboxylase inhibitors: new aryl and heteroaryl analogs of methylglyoxal bis(guanylhydrazone)

  摘要：

  A series of 3-acylbenzamidine (amidino)hydrazones 7a-h, the corresponding (hetero)aromatic congeners 7i-p, and 3,3'-bis-amidino-biaryls 25a-e were synthesized. The hydrazones 7a-p were prepared by conversion of the corresponding acyl nitriles 1a,c-di,n-p to the imido esters 3a,c-d,i and the amidines 5a,c-d,h-i, followed by a reaction with aminoguanidine, or vice versa. Similarly, the biaryl 3,3'-dinitriles 23a-e were converted, via the imino esters 24a-c or the imino thioesters 27d-e, to the diamidines 25a-e. These new products are conformationally constrained analogues of methylglyoxal bis(guanylhydrazone)(MGBG). They are up to 100 times more potent as inhibitors of rat liver S-adenosylmethionine decarboxylase (SAMDC) and generally low potent inhibitors of rat small intestine diamine oxidase (DAO) than MGBG. Some of these SAMDC inhibitors, eg., compounds 7a, 7e, 7i, 25a, and 25d, have shown antiproliferative effects against T24 human bladder carcinoma cells. These products, whose structure-activity relationships are discussed, are of interest as potential anticancer agents and drugs for the treatment of protozoal and Pneumocystis carinii infections.

  DOI：

  10.1021/jm00053a007

文献信息

• [EN] ORGANIC COMPOUND, LIGHT-EMITTING ELEMENT, DISPLAY MODULE, LIGHTING MODULE, LIGHT-EMITTING DEVICE, DISPLAY DEVICE, ELECTRONIC DEVICE, AND LIGHTING DEVICE<br/>[FR] COMPOSÉ ORGANIQUE, ÉLÉMENT ÉLECTROLUMINESCENT, MODULE D'AFFICHAGE, MODULE D'ÉCLAIRAGE, DISPOSITIF ÉLECTROLUMINESCENT, DISPOSITIF D'AFFICHAGE, APPAREIL ÉLECTRONIQUE, ET DISPOSITIF D'ÉCLAIRAGE
  申请人：SEMICONDUCTOR ENERGY LAB

  公开号：WO2016132250A1

  公开（公告）日：2016-08-25

  A novel organic compound that can be used as an electron-injection material or an electron-transport material of a light-emitting element is provided. An organic compound with which a display device having less crosstalk can be obtained is provided. A light-emitting device, a display device, and an electronic device each having less crosstalk are provided. An organic compound including two or three benzo[h]quinazoline rings is provided. In the organic compound, two or three benzo[h]quinazoline rings are preferably included in the substituent including an aromatic ring or a heteroaromatic ring and having 3 to 30 carbon atoms. When two or three benzo[h]quinazoline rings are included in a substituent particularly including a heteroaromatic ring and having 3 to 30 carbon atoms, a high electron-transport property can be obtained.

  提供了一种新型有机化合物，可用作发光元件的电子注入材料或电子传输材料。提供了一种有机化合物，可获得具有较少串扰的显示设备。提供了具有较少串扰的发光装置、显示设备和电子设备。提供了一种包括两个或三个苯并[h]喹唑啉环的有机化合物。在该有机化合物中，最好将两个或三个苯并[h]喹唑啉环包括在取代基中，该取代基包括一个芳香环或杂环芳香环，并具有3至30个碳原子。当将两个或三个苯并[h]喹唑啉环包括在特别包括一个杂环芳香环且具有3至30个碳原子的取代基中时，可以获得高电子传输性能。
• Biarylverbindungen
  申请人：CIBA-GEIGY AG

  公开号：EP0350448A1

  公开（公告）日：1990-01-10

  Verbindungen der Formel I worin X₁, X₂, X₃, X₄, X₅, X₆, Y, Z und R₁-R₄ die in der Beschreibung angegebenen Bedeutungen haben, weisen wertvolle pharmazeutische Eigenschaften auf und sind insbesondere gegen Tumoren wirksam. Sie werden in an sich bekannter Weise hergestellt.

  式 I 的化合物 其中 X₁、X₂、X₃、X₄、X₅、X₆、Y、Z 和 R₁-R₄ 具有说明中给出的含义，具有重要的药用特性，对肿瘤特别有效。它们以已知的方式生产。
• METHYLGLYOXAL BIS(GUANYL-HYDRAZONE) FOR REGULATING OSTEOPONTIN IN A SUBJECT
  申请人：Pathologica LLC

  公开号：EP3228310A1

  公开（公告）日：2017-10-11

  The present invention provides methods for the regulation of osteopontin activity in a subject as well as for treating or preventing conditions associated with an increased activity of osteopontin activity in a subject.

  本发明提供了调节受试者体内骨化素活性以及治疗或预防与受试者体内骨化素活性增加有关的疾病的方法。
• COMPOSITION FOR ORAL DELIVERY COMPRISING MGBG FOR USE IN TREATING MULTIPLE SCLEROSIS
  申请人：Pathologica LLC

  公开号：EP3473247A1

  公开（公告）日：2019-04-24

  The present invention relates to an oral pharmaceutical composition, comprising methylglyoxal bis(guanylhydrazone) (MGBG) together with at least one oral pharmaceutically acceptable excipient, for use in the treatment or delaying the onset or development of multiple sclerosis when orally administered to a subject.

  本发明涉及一种口服药物组合物，包括甲基乙二醛双（鸟苷腙）（MGBG）和至少一种口服药物可接受赋形剂，用于口服给受试者治疗或延缓多发性硬化症的发作或发展。
• MITOGUAZONE FOR PREVENTING THE RELAPSE OR THE PROGRESSION OF MULTIPLE SCLEROSIS
  申请人：Pathologica LLC

  公开号：EP3831372A1

  公开（公告）日：2021-06-09

  Disclosed herein are new oral pharmaceutical compositions of SAMDC inhibitors, polyamine analogs, and polyamine biosynthesis inhibitors, and their application for the treatment of conditions including demyelinating diseases, autoimmune disorders affecting the nervous system, and other neurodegenerative conditions.

  本文公开了SAMDC抑制剂、多胺类似物和多胺生物合成抑制剂的新型口服药物组合物，以及它们在治疗脱髓鞘疾病、影响神经系统的自身免疫性疾病和其他神经退行性疾病等疾病中的应用。